Moderate to Severe Crohn's Disease

Disease

Related News

Risankizumab Data in Crohn’s Disease Show Remission, Durable Response and Low Switch Rates

May 05, 2026

Risankizumab data in Crohn’s disease showed 55% clinical remission at week 12 in AFFIRM, durable efficacy through 148 weeks in SEQUENCE, and the lowest 24-month switch rate in a U.S. claims analysis.

Real-world study reports upadacitinib outcomes in anti-TNF-refractory Crohn’s disease

May 05, 2026

A retrospective real-world study of 108 Chinese patients with anti-TNF-refractory Crohn’s disease found upadacitinib clinical remission rates of 55.1% at week 12 and 52.5% at week 24.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT06450197	Phase IIa Study Evaluating AZD7798 in Crohn's Disease	ACTIVE_NOT_RECRUITING	PHASE2